Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-204"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-204"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Given how important patient compliance and the correct administration of medicinal products are for successful treatment, it is vital that the public, that is, the patients, have access to good quality, non-advertising information that is true, current and not misleading, in line with the Summary of Product Characteristics. The best-placed body to provide current and accurate information for each medicinal product is its marketing authorisation holder. Parliament has rightly decided to focus on and protect the interests of patients. I could not agree more with this approach, although I do not believe that there is any need to limit the possibilities afforded by the Commission’s proposal on disclosure of information by the pharmaceutical industry, under the ‘push principle’. This was a balanced proposal that took the interests of all parties into account, involving health professionals and protecting the public from advertising about medicinal products subject to medical prescription, which quite rightly remains banned. I do not believe the text that has just been adopted will actually change the reality of patient’s access to information much, which I think is a missed opportunity."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples